Adriaan Den Heijer
Executive Vice President and Chief Commercial OfficerAir France-KLM Group
General ManagementView Profile →Head of Genentech Research and Early Development · Roche Group
Aviv Regev leads Genentech Research and Early Development and sits on Roche’s enlarged Corporate Executive Committee. A computational biologist, she previously led research programs at the Broad Institute and held faculty positions at MIT.
Last reviewed: Nov 10, 2026
Head of Genentech Research and Early Development
Roche Group
Last Reviewed: November 10, 2026
Aviv Regev leads Genentech Research and Early Development and sits on Roche’s enlarged Corporate Executive Committee. A computational biologist, she previously led research programs at the Broad Institute and held faculty positions at MIT.
Has led Genentech Research and Early Development since 2020.
Served as founding director of the Klarman Cell Observatory and founding co-chair of the Human Cell Atlas.
Joined the Allen Institute board in 2024 and Broad Institute board in 2025.
Regev began her postdoctoral research career as a Bauer Fellow at Harvard’s Center for Genomics Research from 2003 to 2006. She joined MIT’s Department of Biology as an assistant professor in 2006, became a tenured associate professor in 2011 and a professor in 2015.
She was also a core member of the Broad Institute from 2006 to 2020. In 2012, she became founding director of its Klarman Cell Observatory, and in 2013 she began leading the Cell Circuits Program. She subsequently chaired the faculty and served on the institute’s executive leadership team.
Her research leadership included service as a Howard Hughes Medical Institute investigator from 2014 to 2020. In 2016, she became founding co-chair of the Human Cell Atlas, an international effort to map human cells.
In 2020, Regev became head of Genentech Research and Early Development and joined Roche’s enlarged Corporate Executive Committee. Her scientific work has developed computational approaches for single-cell and spatial genomics, contributions recognized by Carnegie Mellon University’s 2025 Dickson Prize in Science.
Her institutional service continued alongside the Genentech role. She joined the Allen Institute’s board in 2024 and returned to the Broad Institute as a board member in 2025. Her scientific advisory appointments have also included the Arc Institute and the Broad’s Wendy and Eric Schmidt Center.
Regev completed a direct MSc at Tel Aviv University in 1997 and earned a PhD in computational biology there in 2002.